According to a study, GAS5 expression was statistically decreased by 29.94% in the plasma of stage I NSCLC patients, and the combined detection of CEA, CA199, and GAS5 performed well in the early diagnosis of NSCLC [ 108 ] In addition, circulating GAS5 was confirmed as a biomarker to evaluate and monitor NSCLC surgical resection, with an increasing trend seven days after surgery [ 42 , 108 ] Tumor‐derived exosomal GAS5 is also a promising biomarker for NSCLC.
← all excerpts
Circulating noncoding RNAs: promising biomarkers in liquid biopsy for the diagnosis, prognosis, and therapy of NSCLC.
1
—
—